In today’s recent session, 1.41 million shares of the ImmunityBio Inc (NASDAQ:IBRX) have been traded, and its beta is 0.96. Most recently the company’s share price was $8.23, and it changed around -$0.17 or -2.08% from the last close, which brings the market valuation of the company to $5.69B. IBRX at last check was trading at a discount to its 52-week high of $10.53, offering almost -27.95% off that amount. The share price’s 52-week low was $1.25, which indicates that the recent value has risen by an impressive 84.81% since then. We note from ImmunityBio Inc’s average daily trading volume that its 3-month average coming to 7.43 million.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX has been showing red trend so far today with a performance of -2.08% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 63.84% year-to-date, but still up 3.85% over the last five days. On the other hand, ImmunityBio Inc (NASDAQ:IBRX) is 67.17% up in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to decrease their stock price by -2.88% from its current value. Analyst projections state that IBRX is forecast to be at a low of $8 and a high of $8.
ImmunityBio Inc (IBRX) estimates and forecasts
ImmunityBio Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 139.10 percent over the past six months and at a 24.24% annual growth rate that is well above the industry average of 13.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 46.90% in revenue this quarter, and will report an increase of 15.80% in the next quarter. The year-over-year growth rate is expected to be 11,403.20%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of $2.52 million in revenue for the current quarter. 1 analysts expect ImmunityBio Inc to make $10.03 million in revenue for the quarter ending Sep 2024. The company’s sales for the same quarters a year ago were $41k and $82k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 6,046.30%. Forecasts for the next quarter put sales growth at 12,131.70%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.17%. ImmunityBio Inc earnings are expected to increase by 35.22% in 2024, but the outlook is negative -1.70% per year for the next five years.
